Robins Kaplan Named Top Firm for Hatch-Waxman Litigation

Four Partners Named Life Science Stars

October 14, 2022

Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm nationwide for generic pharmaceutical companies. In addition, Jake Holdreith, Jeffrey Hovden, Oren Langer, and Ronald Schutz have been named “Life Science Stars.”

  • Jake Holdreith is a member of the firm’s Executive Board and the leader of the firm’s life sciences group. He has tried jury cases to multi-million-dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Based on his accomplishments, Holdreith was recently named Hatch-Waxman Litigator of the Year – Generic by LMG Life Sciences. He is ranked in the areas of General Patent Litigation, Patent Strategy & Management, and Hatch-Waxman Patent Litigation.
  • Jeff Hovden practices in the area of patent litigation, with a focus on generic pharmaceutical patent cases under the Hatch-Waxman Act and within the biotechnology industry. He has litigated numerous patent infringement and invalidity actions, including many cases involving top-selling worldwide prescription drugs for both generic and name-brand clients. Hovden routinely advises clients on their intellectual property portfolios and has extensive experience with the Food, Drug, and Cosmetic Act's drug-approval provisions and their attendant regulations. He is ranked in the area of Hatch-Waxman Litigation.
  • Oren Langer is Managing Partner of the firm’s New York office. He focuses his practice on intellectual property and technology litigation. His experience spans various industries, including pharmaceuticals (under the Hatch-Waxman Act regulatory framework), chemicals, telecommunications, video gaming, and retail services. Langer also advises clients on licensing negotiations and campaigns, and monetizing intellectual property in anticipation of prospective mergers or acquisitions. He is ranked in the area of Hatch-Waxman Litigation.
  • Ronald Schutz is chair of the firm’s Executive Board. He is a fellow of the American College of Trial Lawyers and has been recognized by many legal organizations and publications as one of the top lawyers in the country, including The National Law Journal, which named him one of the “Top 10 Winning Litigators in the United States.” Schutz has won a nine-figure and multiple eight-figure jury verdicts, and has secured victories against behemoths such as Apple, Clear Channel, Sony, and Canon. He is ranked in the areas of General Patent Litigation and Hatch-Waxman Litigation.

Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Ronald J. Schutz


Immediate Past Chairman
Member of Executive Board

Related Publications

March 22, 2024
‘In re Cellect’:
Derrick Carman - New York Law Journal
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 28, 2023
Data Shows Most SEP Holders Send Pre-Suit Demand Letters - For Good Reason
Aaron Fahrenkrog, Benjamen Linden, Navin Ramalingam - IAM
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top